





Indication	Preclinical	Phase 1	Phase 2	Phase 3	Status
Hospital / Acute					
ABSSSI					CRL from FDA received in February 2019; Type A FDA meeting scheduled for May 3, 2019.
HABP/VABP					Phase 3 preparations completed; funding needed to initiate trial
Pediatric					Preclinical and formulation work ongoing
Persistent / Recurrent					
<i>S. aureus</i> lung infections in cystic fibrosis					Preclinical and formulation work ongoing